Retroviral vectors

Details Retroviral vectors Retroviral vectors

2007-04-03

2007-04-03

Schnizer, Richard (Department: 1635)

Drug, bio-affecting and body treating compositions

Whole live micro-organism, cell, or virus containing

Genetically modified micro-organism, cell, or virus

C435S320100, C435S325000, C435S091330, C536S023720

Reexamination Certificate

active

10661761

ABSTRACT:
Retroviral vector production systems for producing lentivirus-based vector particles which are capable of infecting and transducing non-dividing target cells, wherein one or more of the auxiliary genes such as vpr, vif, tat, and nef in the case of HIV-1 are absent from the system. The systems and resulting retrovirus vector particles have improved safety over existing systems and vectors.

REFERENCES:
patent: 5554524 (1996-09-01), Temin et al.
patent: 5585263 (1996-12-01), Hammarskj old et al.
patent: 5665577 (1997-09-01), Sodroski et al.
patent: 5739118 (1998-04-01), Carrano et al.
patent: 5981505 (1999-11-01), Weiner
patent: 5994136 (1999-11-01), Naldini
patent: 6013516 (2000-01-01), Verma et al.
patent: 6033672 (2000-03-01), Douvas et al.
patent: 6165782 (2000-12-01), Naldini
patent: 6200575 (2001-03-01), Zagury et al.
patent: 6312682 (2001-11-01), Kingsman
patent: 6326007 (2001-12-01), Yilma
patent: 6428953 (2002-08-01), Naldini
patent: 6468539 (2002-10-01), Cohen et al.
patent: 0 213 894 (1986-08-01), None
patent: 0611822 (1994-08-01), None
patent: 0759471 (1997-02-01), None
patent: WO 91/19798 (1991-12-01), None
patent: WO 92/21750 (1992-12-01), None
patent: WO95/30755 (1995-11-01), None
patent: WO 97/12622 (1997-04-01), None
patent: WO 97/14809 (1997-04-01), None
patent: WO97/14809 (1997-04-01), None
Harmache et al (J. Virol. 69(9): 5445-5454, 1995).
Bray et al (Proc. Nat. Acad. Sci. USA 91: 1256-1260, 1994).
Coffin et al (in Retroviruses Cold Spring Harbor Laboratory Press, 1997, p. 58).
Chang et al (Virology 211: 157-169, 1995).
Luznik (J. Clin. Invest. 95: 328-332, 1995).
Kestler et al, “Importance of th enef Gene for Maintenance of High Virus Loads and for Development of AIDS”, Cell 65:651-662 (1991).
Blomer et al., “Highly Efficient and Sustained Gene Transfer in Adult Neurons with a Lentivirus Vector”, Journal of Virology 97, 1997, p. 6641-6649.
Blomer et al., “Applications of gene therapy to the CNS”, Human Molecular Genetics 5, 1996, p. 1397-1404.
Clever et al., RNA Secondary Structure and Binding Sites for gag Gene Products in the 5′ Packaging Signal of Human Immundeficiency Virus Type 1, Journal of Virology 69, 1995, p. 2101-2109.
Clever et al., “Mutant Human Immunodeficiency Virus Type 1 Genomes with Defects in RNA Dimerization or Encapsidation”, Journal of Virology 71, 1997, p. 3407-3414.
John M. Coffin, “Retroviridae: The Virsuses and Their Replication”, Fields of Virology 3, 1996, p. 1767-1996.
Fuller et al., “Vesicular Stomatitis Virus Infects and Matures Only through the Basolateral Surface of the Polarized Epithelial Cell Line, MDCK”, Cell 38, 1984, p. 65-77, p. 65-77.
Harrison et al., “Inhibition of HIV Production in Cells Containing an Integrated, HIV-Regulated Diphtheria Toxin A Chain Gene”, Aids Research and Human Retroviruses 8, 1992, p. 39-45.
Hayashi et al., “RNA Packaging Signal of Human Immunodeficiency Virus Type 1”, Virology 188, 1992, p. 590-599.
Kim et al., “Minimal Requirement for a Lentivirus Vector Based on Human Immunodeficiency Virus Type 1”, Journal of Virology 72, 1998, p. 811-816.
Kim et al., “Temporal Aspects of DNA and RNA Synthesis during Human Immunodeficiency Virus Infection: Evidence for Differential Gene Expression”, Journal of Virology 63, 1989, p. 3708-3713.
Mann et al., “Construction of a Retrovirus Packaging Mutant and Its Use to Produce Helper Free Defective Retroviruses”, Cell, vol. 33, 1983, p. 153-159.
Martarano et al., “Equine Infectious Anemia Virus trans-Regulatory Protein Rev Controls Viral mRNA Stability, Accumulation, and Alternative Splicing”, Journal of Virology 68, 1994, p. 3102-3111.
Payne et al., “Characterization of infectious molecular clones of equine infectious anaemia virus”, Journal of General Virology 75, 1994, p. 425-429.
Yee et al., “A general method for the generation of high-titer, pantropic retroviral vectors: Highly efficient infection of primary hepatocytes”, Proc. Natl. Acad. Sci. USA 91, 1994, p. 9564-9568.
Carroll et al., “E. colibeta-Glucuronidase (GUS) as a Marker for Recombinant Vaccinia Viruses”, BioTechniques 19, 1995, p. 352-354.
Carroll et al., “Host Range and Cytopathogenicity of the Highly Attenuated MVA Strain of Vaccinia Virus: Propagation and Generation of Recombinant Viruses in a Nonhuman Mammalian Cell Line”, Virology 238, 1997, p. 198-211.
Chakrabarti et al., “Vaccinia Viruse expression Vector: Coexpression of beta-Galactosidase Provides Visual Screening of Recombinant Virus Plaques”, Molecular and Cellular Biology, 5, 1985, p. 3403-3409.
Chakrabarti et al., “Compact, Synthetic, Vaccinia Virus Early/Late Promoter for Protein Expression”, BioTechniques 23, 1997, p. 1094-1097.
Davison et al., “Structure of Vaccinia Virus Early Promoters”, J. Mol. Biol. 210, 1989, p. 749-769.
Davison et al. “Structure of Vaccinia Virus Late Promoters”, J. Mol. Biol. 210, 1980, p. 771-784.
Earl et al., “Preparation of Cell Cultures and Vaccinia Virus Stocks”, Current Protocols in Molecular Biology 1998, Suppl. 43 Unit 16.16.
Earl et al., “Generation of Recombinant Vaccinia Viruses”, Current Protocols in Molecular Biology 1998, Suppl. 43 Unit 16.17.
Flexner et al. “Prevention of vaccinia virus infection in immunodeficient mice by vector-directed IL-2 expression”, Nature 330, 1987, p. 259-262.
Holzer et al., “Construction of a Vaccinia Virus Deficient in the Essential DNA Repair Enzyme Uracil DNA Glycosylase by a Complementing Cell Line”, Journal of Virology 71, 1997, p. 4997-5002.
Mackett et al., “Vaccinia virus: A selectable eukaryotic cloning and expression vector”, Proc. Natl. Acad. Sci. USA 79, 1982, p. 7415-7419.
Mahnel et al., “Erfahrungen bei der Schutzimpfung gegen Orthopocken von Mensch und Tier mit dem Impstamm MVA”, English translation, Berl und Munchener Tierartzliche Wochenschrift 107, 1994, p. 253-256.
Mayr et al., “The Smallpox Vaccination Strain MVA: Marker, Genetic Structure, Experience Gained with the Parenteral Vaccination and Behavior in Organisms with a Debilitated Defence Mechansism”, Zentralbl. Bakteriol, 1978, p. 375-390 (English Abstract).
Meyer et al., “Mapping of deletions in the genome of the highly attenuated vaccinia virus MVA and their influence on virulence”, Journal of General Virology 72, 1991, p. 1031-1038.
Bernard Moss, “Poxviridae: The Viruses and Their Replication”, Fields Virology 3, 1996, p. 2637-2672.
Moss et al., “Host Range Restricted Non-Replicating Vaccinia Virus Vectors as Vaccine Candidates”, Adv Exp Med Biol 367, 1996, p. 7-13.
Panicali et al., “Construction of poxviruses as cloning vectors: Insertion of the thymidine kinase gene from herpes simplex virus into the DNA of infectious vaccinia virus”, Proc. Natl. Acad. Sci. USA, 79, 1982, p. 4927-4931.
Soneoka et al., “A transient three-plasmid expression system for the production of high titer retroviral vectors”, Necleic Acids Research, vol. 23, 1995, p. 628-633.
Sutter et al., “Nonreplicating vaccinia vector efficiently expresses recombinant genes”, Proc. Natl. Acad. Sci. USA, 1992, p. 10847-10851.
Taylor et al., “Nonreplicating Viral Vectors as Potential Vaccines: Recombinant Canarypox Virus Expressing Measles Virus Fusion (F) and Hemagglutinin (HA) Glycoproteins”, Virology 187, 1992, p. 321-328.
Paoletti et al., “Safe and Effective Poxvirus Vectors-NYVAC and ALVAC”, Dev Biol Stand 82, 1994, p. 65-69.
Wyatt et al., “Replication-Deficient Vaccinia Virus Encoding Bacteriophage T7 RNA Polymerase for Transient Gene Expression in Mammalian Cells”, Virology 210, 1995, p. 202-205.
Wyatt et al., “Marker Rescue of the Host Range Restriction Defects of Modified Vaccinia Virus Ankara”, Virology

Affiliated with

Also associated with

Rating

Retroviral vectors does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Retroviral vectors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Retroviral vectors will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3790233